Prevest Denpro Limited

BSE: PREVEST543363ISIN INE0GAO01018

Healthcare
Medical Equipment & Supplies

Share price

₹400.00+2.45 (+0.62%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹524.95
52W low: ₹318.15
Off 52W high: -23.80%
1M return: +5.11%
3M return: +4.81%
6M return: -6.54%
1Y return: -23.80%
20D avg volume: 7,940
50 DMA: ₹387.43
200 DMA: ₹405.05

Key ratios Consolidated

Market cap: ₹480.12 Cr
Current price: ₹400.00
52W high / low: ₹524.95 / ₹318.15
Face value: ₹10.00
P/E: —
P/B: —
EPS (TTM): —
Book value / share: —
ROE: —
ROCE: 21.90%
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: —
Dividend yield: 0.25%
Dividend / share (TTM): ₹1.00
Payout: —
Cash conversion cycle: 87.0 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	19.07	—	18.46	—	15.77	18.45	—
	1.32	—	1.15	—	1.17	1.08	—
	20.38	—	19.61	—	16.93	19.53	—
	12.82	—	13.17	—	10.94	12.38	—
	4.80	—	4.66	—	4.06	2.63	—
	0.00	—	0.00	—	0.00	0.00	—
	3.77	—	3.47	—	3.06	2.89	—
	0.00	—	0.00	—	0.00	0.00	—
	—	—	—	—	0.49	0.47	—
	4.24	—	5.44	—	3.84	6.56	—
	7.56	—	6.44	—	5.99	7.15	—
	0.00	—	0.00	—	0.00	0.00	—
	7.56	—	6.44	—	5.99	7.15	—
	1.92	—	1.72	—	1.58	2.01	—
	5.64	—	4.72	—	4.41	5.14	—
	4.70	—	3.93	—	3.67	4.28	—
Key metrics
	7.56	—	6.44	—	6.48	7.62	—
	39.60%	—	34.90%	—	41.10%	41.30%	—
	29.60%	—	25.60%	—	28.00%	27.90%	—
	—	—	—	—	—	6.70%	—
	20.90%	—	—	—	—	—	—
	27.90%	—	—	—	—	—	—

Metric	FY26	FY25	FY24
Income statement
	71.81	63.03	56.43
	4.92	4.07	2.86
	76.72	67.09	59.29
	49.11	42.84	37.86
	17.82	12.63	13.76
	0.00	0.00	—
	13.24	11.35	9.88
	0.00	0.00	—
	2.01	—	1.28
	17.25	17.34	13.15
	27.61	24.25	21.43
	0.00	0.00	0.00
	27.61	24.25	21.43
	7.12	6.09	5.29
	20.49	18.16	16.14
	17.07	15.13	—
Key metrics
	29.62	24.25	22.71
	41.20%	38.50%	40.20%
	28.50%	28.80%	28.60%
	21.90%	22.80%	—
	13.90%	11.70%	—
	12.80%	12.50%	—
	12.92	14.82	—
	0.72	0.82	—
	87.0	81.6	—
Balance sheet
	133.19	112.53	—
	106.49	85.72	—
	72.85	60.90	—
	8.71	7.67	—
	10.89	8.04	—
	3.30	2.31	—
	26.60	26.81	—
	2.49	1.62	—
	7.14	5.96	—
Cash flow
	14.81	14.82	—
	-1.59	-1.33	—
	-1.20	-1.20	—
	1.89	0.00	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24	Q3 FY22
Income statement
	19.44	—	18.38	—	15.72	18.54	—	11.12
	1.33	—	1.16	—	1.17	1.08	—	0.67
	20.77	—	19.54	—	16.90	19.62	—	11.79
	13.07	—	12.66	—	10.68	12.39	—	6.67
	4.80	—	4.66	—	4.06	4.08	—	2.52
	0.00	—	0.00	—	0.00	0.00	—	—
	3.38	—	3.07	—	2.71	2.59	—	1.57
	0.00	—	0.00	—	0.00	0.00	—	0.02
	0.52	—	0.51	—	0.49	0.47	—	0.13
	4.48	—	5.29	—	3.92	5.31	—	2.16
	7.70	—	6.87	—	6.21	7.24	—	5.12
	7.70	—	6.87	—	6.21	7.24	—	5.12
	1.92	—	1.72	—	1.58	1.99	—	1.37
	5.78	—	5.15	—	4.63	5.25	—	3.75
	4.82	—	4.29	—	3.86	4.37	—	—
Key metrics
	8.22	—	7.38	—	6.70	7.71	—	5.27
	42.30%	—	40.20%	—	42.60%	41.60%	—	47.40%
	29.70%	—	28.00%	—	29.50%	28.30%	—	33.70%
	—	—	—	—	—	6.80%	—	—
	23.70%	—	—	—	—	—	—	—
	24.80%	—	—	—	—	—	—	—

Metric	FY26	FY25	FY24	FY23	FY22
Income statement
	71.66	63.07	56.44	49.85	37.62
	5.00	4.11	2.86	2.03	2.11
	76.66	67.18	59.30	51.89	39.73
	48.12	42.91	37.89	30.93	23.68
	17.82	14.08	14.17	12.76	9.87
	0.00	0.00	—	—	—
	11.80	10.27	9.54	8.19	6.52
	0.00	0.00	—	—	0.10
	1.99	1.90	1.28	0.68	0.52
	17.69	16.92	13.08	9.46	6.75
	28.54	24.27	21.41	20.96	16.05
	28.54	24.27	21.41	20.96	16.05
	7.12	6.07	5.29	5.25	4.48
	21.42	18.20	16.12	15.71	11.57
	17.84	15.16	—	—	9.64
Key metrics
	30.53	26.17	22.69	21.64	16.67
	42.60%	41.50%	40.20%	43.40%	44.30%
	29.90%	28.90%	28.60%	31.50%	30.80%
	22.50%	22.80%	—	—	—
	13.60%	11.70%	13.20%	32.50%	—
	17.70%	12.90%	2.60%	35.80%	—
	14.09	13.03	—	—	—
	0.74	0.82	—	—	—
	87.1	81.6	—	—	—
Balance sheet
	134.24	112.67	—	—	—
	106.06	85.40	—	—	—
	72.65	60.46	—	—	—
	8.79	7.81	—	—	—
	10.73	7.89	—	—	—
	3.16	2.30	—	—	—
	26.57	26.80	—	—	—
	2.43	1.60	—	—	—
	7.17	6.07	—	—	—
Cash flow
	15.86	14.98	—	—	—
	-2.47	-1.74	—	—	—
	-1.20	-1.20	—	—	—
	1.77	1.95	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +12.86%
Sales CAGR 5Y: —
Profit CAGR 3Y: +10.89%
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 73.61%

Quarter	September 2026	June 2026
Promoter %	73.61%	73.61%

Holder	Type	Holding	Previous	Change
ATUL MODI	Promoter	37.52%	37.52%	0.00%
NAMRATA MODI	Promoter	36.03%	36.03%	0.00%
ASHIKA GLOBAL FINANCE PRIVATE LIMITED	Public	2.79%	1.13%	+1.66%
THERMO CAPITAL PRIVATE LIMITED	Public	1.50%	1.30%	+0.20%
SHARAD KANAYALAL SHAH	Public	1.08%	1.08%	0.00%
Girish Paman Vanvari	Public	1.01%	1.02%	-0.01%
ALKA BEOTRA	Promoter Group	0.03%	0.03%	0.00%
NIHARIKA MODI	Promoter Group	0.03%	0.03%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Poly Medicure Ltd	16,093	1,587.65	51.43	13.20%	+18.31% TTM	-12.49% TTM	-18.70%
MOLBIO DIAGNOSTICS LIMITED	15,901	1,379.80	—	—	—	—	—
Sahajanand Medical Technologies Limited	4,939	485.85	—	—	—	—	—
FISCHER MEDICAL VENTURES LIMITED	1,655	25.29	59.29	12.70%	+195.94% TTM	+371.52% TTM	-73.00%
Tarsons Products Limited	1,651	310.35	148.83	4.80%	+10.63% TTM	-59.68% TTM	+7.85%
Laxmi Dental Limited	1,036	188.30	31.98	11.50%	+13.07% TTM	+24.85% TTM	-40.71%
Hemant Surgical Industries Limited	884	608.10	—	19.50%	—	—	+109.69%
Fabtech Technologies Limited	591	133.05	16.61	11.60%	—	—	-44.16%
Prevest Denpro Limited	480	400.00	—	21.90%	—	—	-23.80%
Nureca Limited	288	301.65	60.46	3.40%	+33.66% TTM	+15.82% TTM	+17.10%
EARKART LIMITED S	161	117.00	32.59	12.10%	—	—	-48.46%
CHOKSI ASIA LIMITED S	120	210.00	23.08	18.40%	+21.40% TTM	+132.74% TTM	+97.28%
Shree Pacetronix Ltd	63	169.15	19.60	25.00%	+22.63% TTM	+208.57% TTM	-38.65%
Amkay Products Limited S	46	53.50	20.04	13.40%	—	—	+13.88%
KMS Medisurgi Limited S	44	132.80	177.07	4.80%	—	—	—
Royal Sense Limited	36	67.70	—	26.10%	—	—	-70.69%
GKB Ophthalmics Ltd.	31	62.00	5.67	9.60%	+29.95% TTM	+170.50% TTM	-9.48%
Centenial Surgical Suture Ltd. S	26	71.96	-17.99	2.60%	+6.70% TTM	+26.29% TTM	-33.37%
Transpact Enterprises Limited S	4	100.70	—	14.50%	—	—	-57.35%

Some figures use IPO-document inputs. Growth periods are shown per value; FY means annual.

Filings & corporate actions

Recent announcements

Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended September 30, 202613 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer report and Voting results of the AGM held on September 17, 2026.19 Sep 2026 · AGM/EGM / AGM
Proceeding of the AGM held on September 17, 202617 Sep 2026 · AGM/EGM / AGM
Newspaper Publication regarding 27th Annual General Meeting and remote E-Voting information21 Aug 2026 · Company Update / Newspaper Publication
The Company has sent letter to the shareholders for AGM whose email id was not registered with RTA.20 Aug 2026 · Company Update / General
Please find enclosed herewith Annual Report for Financial year 25-26.20 Aug 2026 · Others / Reg. 34 (1) Annual Report
27th AGM of the Company is scheduled to be held on Thursday, September 17, 2026 at 12:30 p.m. through VC/OAVM.20 Aug 2026 · AGM/EGM / AGM
Newspaper Advertisement for Notice of AGM to be held through VC/OAVM.19 Aug 2026 · Company Update / Newspaper Publication
Press Release regarding Financial Results of the Company for the quarter ended June 30, 2026, along with the declaration of dividend at the rate of 10% i.e. Rs. 1/- per Equity Share.11 Aug 2026 · Company Update / Press Release / Media Release
Notice of Record Date.11 Aug 2026 · Corp. Action / Record Date
The Board of Directors at its Meeting held today i.e. August 11, 2026 have considered and approved the unaudited financial results of the Company (standalone and consolidated) for quarter ....11 Aug 2026 · Result / Financial Results
The Company at its Board Meeting held today i.e. August 11, 2026 have approved Unaudited Financial Results of the Company (standalone and consolidated) for quarter ended June 30, 2026 and ....11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Prevest Denpro Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....5 Aug 2026 · Board Meeting / Board Meeting
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for quarter ended June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Transcript for Earning''s call held on 29th June, 20262 Jul 2026 · Company Update / Earnings Call Transcript
Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read along with SEBI (Listing Obligations & Disclosure Requirements) (Second ....29 Jun 2026 · Company Update / Analyst / Investor Meet
Investor Presentation to be made to Analysts/Investor on the Financial Results for financial year ended March 31, 202627 Jun 2026 · Company Update / Investor Presentation
Intimation of Closure of Trading Window.27 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Earnings Discussion is rescheduled to be held on June 29, 2026 at 03:00 p.m.23 Jun 2026 · Company Update / Analyst / Investor Meet
Non-Applicability of Annual Secretarial Compliance Report for the Financial year ended March 31, 202630 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
This is to inform you that the Earnings conference call scheduled to be held on June 02, 2026 has been cancelled due to unforeseen circumstances.29 May 2026 · Company Update / General
Intimation of Analyst / Institutional Investor Meeting to be held on, Tuesday, 02nd June 2026 at 4.00 PM.27 May 2026 · Company Update / Analyst / Investor Meet
The Company has appointed M/s. ADV & Associates, Chartered Accountants as Statutory Auditor of the Company for a period of 5 years, subject to approval of Members of the Company.27 May 2026 · Company Update / Appointment of Statutory Auditor/s
The Company at its meeting held today i.e., May 27, 2026 has appointed Internal Auditor, Cost Auditor, Secretarial Auditor and Statutory Auditor of the Company.27 May 2026 · Company Update / General
The Company at its meeting held today i.e., May 27, 2026 has appointed Mr. Sukhen Pal Babuta as Additional Director (Non Executive Independent Director) of the Company.27 May 2026 · Company Update / Change in Management
The Company at its meeting held today i.e., May 27, 2026, has appointed Mr. Pratul Gupta as Company Secretary and Compliance Officer of the Companty27 May 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Audited Financial Results of the Company for quarter and financial year ended March 31, 202627 May 2026 · Result / Financial Results
The Board of Directors at its Meeting held today have approved Audited Financial Results of the Company for quarter and financial year ended March 31, 202627 May 2026 · Board Meeting / Outcome of Board Meeting
Prevest Denpro Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Audited Financial Results of ....21 May 2026 · Board Meeting / Board Meeting
The Board of Directors has approved subscription to the share capital of Prevest Denpro Gulf General Trading LLC, a wholly owned subsidiary for a amount upto AED 5,00,000 to be invested ....5 May 2026 · Company Update / General
Cessation of Mr. Pardeep Gandotra as Independent Director of the Company due to completion of tenure.27 Apr 2026 · Company Update / Change in Directorate
Appointment of Mr. Piyush Kiranprakash Gupta and Mr. Abhijeet Sadashiv Haridas as Additional Directors in the capacity of Non-Executive Independent Director.22 Apr 2026 · Company Update / Change in Directorate
Cessation of Mr. Sudeep Murthy and Mr. Nikhil Shrikant Bobade as Independent Director of the Company due to completion of tenure.21 Apr 2026 · Company Update / Change in Directorate
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended March 31, 2026.8 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Resignation of Mr. Aman Sadhotra from the post of Company Secretary and Compliance officer w.e.f April 06, 2026.6 Apr 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Intimation of Closure of Trading Window27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.14 Feb 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Considered and approved the unaudited financial results of the Company for quarter ended December 31, 2025.14 Feb 2026 · Result / Financial Results
Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 202514 Feb 2026 · Board Meeting / Outcome of Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	4 Sep 2026	5 Sep 2026	—
Final Dividend - Rs. - 1.0000	3 Sep 2025	3 Sep 2025	—
Final Dividend - Rs. - 1.0000	30 Aug 2024	30 Aug 2024	—

Board meetings

11 Aug 2026 Board Meeting - Financial Results